Mohamed Salama, M.D., Discusses CD30 as a Predictive Marker for Therapy

By Kelley Luedke • September 25, 2018

Share this:

In a recent Q&A in CAP Today, the following question was asked: "Is CD30 currently being used as a predictive marker for therapy?"

Mohamed Salama, M.D., Medical Director of Mayo Medical Laboratories, co-authored the response. According to the authors, CD30 is a transmembrane phosphorylated glycoprotein and a member of the tumor necrosis factor receptor superfamily 8 (TNFRSF8). In the hematopoietic system, CD30 is expressed on normal activated T and B cells, as well as virally transformed T and B cells.

The authors stated that the use of CD30 as a predictive marker for therapy is relatively young. While in most of the tumors treated with brentuximab vedotin the CD30 expression is constitutive (for example, CHL, ALCL, GCT), there has been no well-established cutoff for percent or intensity of CD30 expression in tumor cells that leads to an effective response.

Read the full response.

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.